Tamoxifen, esterified estradiol, and physiologic concentrations of estradiol inhibit oxidation of low-density lipoprotein by endothelial cells

被引:15
作者
Kuohung, V
Shwaery, GT
Keaney, JF
机构
[1] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA
关键词
estrogens; low-density lipoprotein; antioxidants; endothelial cell;
D O I
10.1067/mob.2001.115229
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: We investigated the antioxidant effect of tamoxifen, esterified estradiol, and physiologic concentrations of 17 beta -estradiol on endothelial cell-mediated oxidation of low-density lipoprotein. STUDY DESIGN: Human umbilical vein endothelial cells were preincubated with nanomolar concentrations of estradiol, estradiol stearate, and tamoxifen. Low-density lipoprotein was isolated and incubated with cells in serum-free medium. Oxidation of low-density lipoprotein was quantified after 8, 16, and 24 hours of incubation as the formation of thiobarbituric acid-reactive substances. RESULTS: Compared with control, preincubation of human umbilical vein endothelial cells with 1- or 10-nmol/L estradiol resulted in a 12% reduction in the formation of thiobarbituric acid-reactive substances at 24 hours. Preincubation of human umbilical vein endothelial cells with either 10-nmol/L estradiol 17-stearate or 10-nmol/L tamoxifen resulted in 26% and 20% decreases, respectively, in formation of thiobarbituric acid-reactive substances at 24 hours. The difference in the reduction in thiobarbituric acid-reactive substances between control and treatment wells became more pronounced over time. CONCLUSION: Under these experimental conditions, tamoxifen, esterified estradiol, and physiologic concentrations of exogenous estradiol inhibit oxidation of low-density lipoprotein by human umbilical vein endothelial cells.
引用
收藏
页码:1060 / 1063
页数:4
相关论文
共 10 条
[1]  
Beuge J.A., 1978, METHOD ENZYMOL, V52, P302
[2]   CARDIOVASCULAR MORTALITY AND NONCONTRACEPTIVE USE OF ESTROGEN IN WOMEN - RESULTS FROM THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY [J].
BUSH, TL ;
BARRETTCONNOR, E ;
COWAN, LD ;
CRIQUI, MH ;
WALLACE, RB ;
SUCHINDRAN, CM ;
TYROLER, HA ;
RIFKIND, BM .
CIRCULATION, 1987, 75 (06) :1102-1109
[3]  
CHUNG BH, 1986, METHOD ENZYMOL, V128, P181
[4]   ESTROGENS INHIBIT COPPER AND CELL-MEDIATED MODIFICATION OF LOW-DENSITY-LIPOPROTEIN [J].
MAZIERE, C ;
AUCLAIR, M ;
RONVEAUX, MF ;
SALMON, S ;
SANTUS, R ;
MAZIERE, JC .
ATHEROSCLEROSIS, 1991, 89 (2-3) :175-182
[5]   FATAL MYOCARDIAL-INFARCTION IN THE SCOTTISH ADJUVANT TAMOXIFEN TRIAL [J].
MCDONALD, CC ;
STEWART, HJ .
BRITISH MEDICAL JOURNAL, 1991, 303 (6800) :435-437
[7]  
RETSKY KL, 1993, J BIOL CHEM, V268, P1304
[8]   TYPE-IV COLLAGENASE(S) AND TIMPS MODULATE ENDOTHELIAL-CELL MORPHOGENESIS IN-VITRO [J].
SCHNAPER, HW ;
GRANT, DS ;
STETLERSTEVENSON, WG ;
FRIDMAN, R ;
DORAZI, G ;
MURPHY, AN ;
BIRD, RE ;
HOYTHYA, M ;
FUERST, TR ;
FRENCH, DL ;
QUIGLEY, JP ;
KLEINMAN, HK .
JOURNAL OF CELLULAR PHYSIOLOGY, 1993, 156 (02) :235-246
[9]  
Shwaery GT, 1997, CIRCULATION, V95, P1378
[10]   PROTECTIVE ACTIONS OF TAMOXIFEN AND 4-HYDROXYTAMOXIFEN AGAINST OXIDATIVE DAMAGE TO HUMAN LOW-DENSITY LIPOPROTEINS - A MECHANISM ACCOUNTING FOR THE CARDIOPROTECTIVE ACTION OF TAMOXIFEN [J].
WISEMAN, H ;
PAGANGA, G ;
RICEEVANS, C ;
HALLIWELL, B .
BIOCHEMICAL JOURNAL, 1993, 292 :635-638